ClinicalTrials.gg
CompletedNCT05053672Updated Jul 25, 2022

ReOxy Therapy in the Rehabilitation of Chronic Low Back Pain Patients With Comorbidity

An interventional study of ReOxy and Sham ReOxy in Low Back Pain, sponsored by Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-25.

Sponsored by Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The aim of this study is to assess the effect of the respiratory therapy method based on short-term intermittent exposures to hypoxia and hyperoxia (ReOxy therapy) on the pain intensity, restoration of the lumbar range of motion, physical capacity, disability, mental and vegetative status in Chronic Low Back Pain patients with Multiple Chronic Conditions.

Read the detailed description

This is a randomized, single-blinded, placebo-controlled trial, with chronic non-specific low back pain with multiple chronic conditions. Comorbidity constitutes a serious challenge for rehabilitative medicine - significantly reduces the patients' quality of life and restoration of the working capacity.

The objective of the present study will be to evaluate the effectiveness of the combined non-medicinal rehabilitation programe which include a course of ReOxy- therapy and conventional therapy back pain treatment.

90 patients will be randomly allocated to three treatment groups: experimental ("hypoxic group" - ReOxy therapy + conventional therapy back pain treatment), placebo ("sham hypoxic group"- sham- ReOxy therapy + conventional therapy back pain treatment) and control (only conventional therapy back pain treatment).

The clinical outcomes will be obtained at the completion of treatment (2 weeks) and at 1 month after randomization. The statistical analysis will follow the intention-to-treat principles and the between-group differences will be calculated by using mixed linear models.

The outcomes of interest are pain intensity, lumbar range of motion function, general physical and mental status.

02

Conditions studied

  • Low Back Pain

Browse trials for

Keywords

  • low back pain
  • chronic lumbar back pain
03

In context

Low Back Pain

2,930 studies on the registry are indexed under Low Back Pain; 581 are open to participants now.

This study's enrollment of 90 is above the median of 60 across 2,369 interventional studies indexed under Low Back Pain.

Browse Low Back Pain studies →

Lead sponsor

Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with non-specific chronic low back pain for at least 3 months;
  • A pain intensity of at least 5 points measured by 0 -10 points pain rating scale;
  • Co-morbidity - IHD and/or CHF and/or and/or chronic bronchitis)
  • Willing and able to consent, complete all assessment and study procedures;

Exclusion criteria

Exclusion Criteria:

  • Specific types of back pain ( cancer or bone cancer or secondary cancers, vertebral fractures, spinal infection, active inflammatory disease);
  • Low back surgery within past 3 months;
  • Serious cardiovascular, cerebrovascular, neuromuscular and other systemic diseases or other diseases affecting physical activity;
  • Any significant systemic illness or medical condition that could affect safety or compliance with study;
  • Major active or chronic unstable psychiatric illness (e.g. depression, bipolar disorder, obsessive compulsive disorder, schizophrenia) within the previous year;
  • Tumour disease except being successfully treated and off treatment with >2 years. Tumour disease except being successfully treated and off treatment with >2 years.
  • Use of other agents or interventions one month prior to entry and for the duration of the trial;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (actual)

Study arms

  • No intervention
    Conventional therapy back pain treatment

    Participants randomized to сonventional therapy group will receive complex rehabilitation program including physical exercise, phonophoresis with hydrocortisone, lumbar region massage, acupuncture within 2 weeks.

  • Active comparator
    Conventional physiotherapy therapy back pain treatment + ReOxy-therapy

    Participants randomized to Active Comparator group will receive complex rehabilitation program and 10 ReOxy-therapy sessions within 2 weeks (5 sessions per week).

    Device: ReOxy

  • Placebo comparator
    Conventional physiotherapy therapy + Sham ReOxy-therapy

    Participants randomized to Placebo Comparator group will receive complex rehabilitation program and 10 sham ReOxy-therapy sessions within 2 weeks (5 sessions per week).

    Device: Sham ReOxy

Interventions

  • DeviceReOxy

    ReOxy therapy is a protocol which employs passive (the patient is at rest), short (up to 10 min) mild normobaric hypoxic exposures alternated with similar duration intervals of breathing hyperoxia (up to 5 min). The gas mixtures are supplied to a patient via facial mask on continued measuring of oxygenation status of the patients, lasting about 45 min in total per treatment session. The hypoxic load will be individually adjusted, based on the results of a preliminary hypoxic test. The patient inhales air with low oxygen content (10-14%) at atmospheric pressure in a continuous mode through a mask withing 10-min. During the ReOxy - treatment session, the software automatically adjusts the gas mixture switching, based on changes in physiological parameters (blood oxygen saturation and heart rate) in response to hypoxic and hyperoxic impact (biofeedback control).

  • DeviceSham ReOxy

    Placebo treatment with 'sham' ambient air breathing to simulate ReOxy-therapy sessions. Placebo-mode breathing set visually similar to standard breathing set but have a mask with open intake valve. The masks are chosen in a way to provide maximum degree of similarity to reduce the risk of unblinding on the patient-side.

06

What researchers measure

Primary outcomes

  1. Back pain intensity will be measured by the Visual Analog Scale

    Visual analogue scale (VAS) is a simple and frequently used method for the assessment of variations in intensity of pain. The VAS consists of a 10cm horizontal line with the words "no pain" and "worst pain" at the line's end. VAS is a reliable and valid tool to reliable and valid tool to measure pain intensity measure pain intensity.

    Time frame: Baseline, end of the 2-nd week

Secondary outcomes

  1. Back pain intensity

    Back pain intensity will be measured by the Visual Analog Scale Visual analogue scale (VAS) is a simple and frequently used method for the assessment of variations in intensity of pain. The VAS consists of a 10cm horizontal line with the words "no pain" and "worst pain" at the line's end. VAS is a reliable and valid tool to reliable and valid tool to measure pain intensity measure pain intensity.

    Time frame: Baseline and 1-month post randomization

  2. Roland Disability Questionnaire (RDQ)

    The Roland-Morris Questionnaire is a self-administered disability measure in which greater levels of disability are reflected by higher numbers on a 24-point scale

    Time frame: Baseline and 1-month post randomization

  3. Lumbar Range of Motion

    Will be evaluated through the finger-to-floor test. Participant try to reach the floor with his fingertip by bending forward in the same time knees are kept extended. The distance between fingertips and floor are measured in centimetres by examiner.

    Time frame: Baseline, end of the 2-nd week

  4. Change of lower back flexibility

    Will be evaluated through Schober test (positive/negative). The examiner places one finger 5cm below the mark pproximately at the level of L5 and another finger at about 10cm above this mark. The patient is then instructed to touch his toes. If the increase in distance between the two fingers on the patients spine is less than 5cm then this is indicative of a limitation of lumbar flexion.

    Time frame: Baseline, end of the 2-nd week

  5. 6 min-walking test distance

    Change in walking distance in meters during a 6-min period over a corridor of 30m length

    Time frame: Baseline, end of the 2-nd week

  6. Hospital Anxiety and Depression Scale, HADS

    The Hospital Anxiety and Depression Scale (HADS) is a questionnaire, comprising fourteen questions. Each item on the questionnaire is scored from 0-3. The scale is devided into 2 parts: (1) anxiety (minimum score 0, maximum sore 21) and (2) depression (minimum score 0, maximum sore 21). Scoring : 0-7- normal, 8-10-borderling abnormal, 11-21-abnormal

    Time frame: Baseline and 1-month post randomization

  7. Bergen Insomnia Scale (BIS)

    The BIS comprises six items that assesses symptoms of insomnia based on the insomnia criteria found in the Diagnostic and Statistical Manual of Mental Disorders-IV-TR (American Psychiatric Association). Higher values indicate higher levels of insomnia severity.

    Time frame: Baseline and 1-month post randomization

Other outcomes

  1. HR recovery after the 6-minute walk test

    HR recovery measured by sphygmomanometer after the 6-minute walk test

    Time frame: Baseline and end of the 2-nd week

  2. SAD/DAD recovery after the 6-minute walk test

    SAD/DAD recovery measured by sphygmomanometer after the 6-minute walk test

    Time frame: Baseline and end of the 2-nd week

07

Study locations

1 site
  • Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine, Dept. No. 9
    Moscow, Russian Federation
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Apr 2022, 10 months.

Of 1,234 non-industry interventional studies with no phase under Low Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 26. This study's 10 months is close to that.

Counting every sponsor, half of 1,290 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2021
First posted
Sep 22, 2021
StartActual
Jun 1, 2021
Primary completionActual
Apr 15, 2022
CompletionActual
Apr 20, 2022
Last update
Jul 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05053672
Lead sponsor
Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine
Responsible party
Sponsor
First posted
Sep 22, 2021
Start date
Jun 1, 2021
Primary completion
Apr 15, 2022
Completion
Apr 20, 2022
Last update
Jul 25, 2022

Study contacts

Nadezhda Lyamina, M.D.
principal investigator · Moscow Scientific and Practical Center of Medical Rehabilitation, Restorative and Sports Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion